Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (BST:2TZ)

Germany · Delayed Price · Currency is EUR

2.220

+0.020 (0.91%)

At close: Oct 9, 2026

Market Cap	3.18B -8.1%
Revenue (ttm)	608.39M -21.2%
Net Income	109.29M -75.8%
EPS	0.14 -75.7%
Shares Out	n/a
PE Ratio	29.07
Forward PE	n/a
Dividend	0.60 (26.90%)
Ex-Dividend Date	Jun 29, 2026

Volume	n/a
Open	2.220
Previous Close	2.200
Day's Range	2.220 - 2.240
52-Week Range	2.080 - 3.169
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 31, 2026

About BST:2TZ

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited engages in the research, development, processing, manufacturing, and sale of traditional Chinese medicine in China. It provides pharmaceutical products for cardiovascular and cerebrovascular, skin wound repair, health preservation, respiratory, digestion, rheumatism and osteodynia, urological, gynecological and pediatric, ophthalmological, tumor, chronic, and other diseases, as well as tonic drugs. The company was formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Li... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1915

Employees 3,890

Stock Exchange Stuttgart Stock Exchange

Ticker Symbol 2TZ

Financial Performance

In 2025, BST:2TZ's revenue was 4.92 billion, a decrease of -32.70% compared to the previous year's 7.31 billion. Earnings were 2.13 billion, a decrease of -4.41%.

Financial numbers in CNY Financial Statements